Insider Selling: Vera Therapeutics (NASDAQ:VERA) COO Sells 2,579 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) COO David Lee Johnson sold 2,579 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $108,266.42. Following the sale, the chief operating officer owned 45,727 shares in the company, valued at $1,919,619.46. The trade was a 5.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Vera Therapeutics Price Performance

Shares of VERA traded down $0.69 during midday trading on Wednesday, reaching $41.68. The stock had a trading volume of 776,869 shares, compared to its average volume of 897,432. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of -10.45 and a beta of 1.16. The company’s 50-day moving average is $46.63 and its 200 day moving average is $35.30. Vera Therapeutics, Inc. has a 12-month low of $18.53 and a 12-month high of $56.05.

Analysts Set New Price Targets

VERA has been the topic of several research reports. The Goldman Sachs Group lifted their price target on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Wedbush increased their target price on shares of Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, January 21st. Evercore upped their price target on shares of Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Finally, Pivotal Research set a $73.00 price objective on Vera Therapeutics in a report on Friday, December 5th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.18.

Hedge Funds Weigh In On Vera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares during the period. Los Angeles Capital Management LLC bought a new position in Vera Therapeutics during the 4th quarter valued at approximately $46,000. Quantbot Technologies LP bought a new position in Vera Therapeutics during the 2nd quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Vera Therapeutics in the 4th quarter worth approximately $71,000. Finally, Virtus Investment Advisers LLC grew its position in shares of Vera Therapeutics by 14.8% in the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after buying an additional 539 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.